Log in to save to my catalogue

Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure

Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7724923

Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure

Publication information

Publisher

United States: Massachusetts Medical Society

More information

Scope and Contents

Contents

Asciminib, a novel ABL tyrosine kinase inhibitor that targets the myristoyl site of the molecule rather than the ATP-binding domain, showed mainly low-grade toxic effects in a minority of patients and considerable antileukemic activity in the majority of those who had resistance to or unacceptable side effects from standard TKIs.

Alternative Titles

Full title

Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7724923

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7724923

Other Identifiers

ISSN

0028-4793

E-ISSN

1533-4406

DOI

10.1056/NEJMoa1902328

How to access this item